Does the media favor ARVN or SION?

In the previous week, Sionna Therapeutics had 1 more articles in the media than Arvinas. MarketBeat recorded 3 mentions for Sionna Therapeutics and 2 mentions for Arvinas. Sionna Therapeutics' average media sentiment score of 1.22 beat Arvinas' score of 0.60 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARVN or AMLX?

In the previous week, Amylyx Pharmaceuticals had 3 more articles in the media than Arvinas. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 2 mentions for Arvinas. Amylyx Pharmaceuticals' average media sentiment score of 1.17 beat Arvinas' score of 0.60 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, HRMY or ARVN?

Harmony Biosciences has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harmony Biosciences $899.11M 2.27 $158.69M $2.48 14.21 Arvinas $89.40M 5.80 -$80.80M -$3.32 N/A

Is HRMY or ARVN more profitable?

Harmony Biosciences has a net margin of 16.20% compared to Arvinas' net margin of -247.54%. Harmony Biosciences' return on equity of 17.19% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Harmony Biosciences 16.20% 17.19% 11.99% Arvinas -247.54% -44.38% -28.38%

Does the media refer more to HRMY or ARVN?

In the previous week, Harmony Biosciences had 8 more articles in the media than Arvinas. MarketBeat recorded 10 mentions for Harmony Biosciences and 2 mentions for Arvinas. Harmony Biosciences' average media sentiment score of 1.17 beat Arvinas' score of 0.60 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ARVN or NBTX?

Nanobiotix has lower revenue, but higher earnings than Arvinas. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arvinas $89.40M 5.80 -$80.80M -$3.32 N/A Nanobiotix $29.64M 65.54 -$27.11M N/A N/A

Is ARVN or NBTX more profitable?

Nanobiotix has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Nanobiotix's return on equity of 0.00% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas -247.54% -44.38% -28.38% Nanobiotix N/A N/A N/A

Does the media favor ARVN or NBTX?

In the previous week, Arvinas and Arvinas both had 2 articles in the media. Nanobiotix's average media sentiment score of 0.67 beat Arvinas' score of 0.60 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, URGN or ARVN?

Arvinas has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 16.97 -$153.49M -$2.75 N/A Arvinas $89.40M 5.80 -$80.80M -$3.32 N/A

Is URGN or ARVN more profitable?

Urogen Pharma has a net margin of -94.83% compared to Arvinas' net margin of -247.54%. Urogen Pharma's return on equity of 0.00% beat Arvinas' return on equity. Company Net Margins Return on Equity Return on Assets Urogen Pharma -94.83% N/A -62.85% Arvinas -247.54% -44.38% -28.38%

Does the media refer more to URGN or ARVN?

In the previous week, Urogen Pharma had 7 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Urogen Pharma and 2 mentions for Arvinas. Urogen Pharma's average media sentiment score of 0.97 beat Arvinas' score of 0.60 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arvinas (ARVN) Competitors

$8.05 +0.02 (+0.25%)

As of 08:54 AM Eastern

Compare

ARVN vs. SION, AMLX, HRMY, NBTX, and URGN

Should you buy Arvinas stock or one of its competitors? MarketBeat compares Arvinas with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arvinas include Sionna Therapeutics (SION), Amylyx Pharmaceuticals (AMLX), Harmony Biosciences (HRMY), Nanobiotix (NBTX), and Urogen Pharma (URGN).

How does Arvinas compare to Sionna Therapeutics?

Arvinas (NASDAQ:ARVN) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

95.2% of Arvinas shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sionna Therapeutics had 1 more articles in the media than Arvinas. MarketBeat recorded 3 mentions for Sionna Therapeutics and 2 mentions for Arvinas. Sionna Therapeutics' average media sentiment score of 1.22 beat Arvinas' score of 0.60 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas presently has a consensus price target of $15.42, indicating a potential upside of 91.99%. Sionna Therapeutics has a consensus price target of $53.22, indicating a potential upside of 12.93%. Given Arvinas' higher probable upside, equities research analysts plainly believe Arvinas is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Sionna Therapeutics has lower revenue, but higher earnings than Arvinas. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$89.40M	5.80	-$80.80M	-$3.32	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Sionna Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Sionna Therapeutics' return on equity of -27.31% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Arvinas has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Summary

Sionna Therapeutics beats Arvinas on 9 of the 16 factors compared between the two stocks.

How does Arvinas compare to Amylyx Pharmaceuticals?

Arvinas (NASDAQ:ARVN) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Arvinas has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$89.40M	5.80	-$80.80M	-$3.32	N/A
Amylyx Pharmaceuticals	$87.37M	25.85	-$144.74M	-$1.50	N/A

Arvinas has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, suggesting that its stock price is 121% less volatile than the broader market.

Arvinas presently has a consensus price target of $15.42, indicating a potential upside of 91.99%. Amylyx Pharmaceuticals has a consensus price target of $24.63, indicating a potential upside of 21.25%. Given Arvinas' higher probable upside, research analysts plainly believe Arvinas is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 7.3% of Arvinas shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Amylyx Pharmaceuticals had 3 more articles in the media than Arvinas. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 2 mentions for Arvinas. Amylyx Pharmaceuticals' average media sentiment score of 1.17 beat Arvinas' score of 0.60 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amylyx Pharmaceuticals beats Arvinas on 9 of the 16 factors compared between the two stocks.

How does Arvinas compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Arvinas (NASDAQ:ARVN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Harmony Biosciences has a net margin of 16.20% compared to Arvinas' net margin of -247.54%. Harmony Biosciences' return on equity of 17.19% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Arvinas	-247.54%	-44.38%	-28.38%

In the previous week, Harmony Biosciences had 8 more articles in the media than Arvinas. MarketBeat recorded 10 mentions for Harmony Biosciences and 2 mentions for Arvinas. Harmony Biosciences' average media sentiment score of 1.17 beat Arvinas' score of 0.60 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harmony Biosciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$899.11M	2.27	$158.69M	$2.48	14.21
Arvinas	$89.40M	5.80	-$80.80M	-$3.32	N/A

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Harmony Biosciences presently has a consensus price target of $42.63, indicating a potential upside of 20.96%. Arvinas has a consensus price target of $15.42, indicating a potential upside of 91.99%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Harmony Biosciences beats Arvinas on 12 of the 17 factors compared between the two stocks.

How does Arvinas compare to Nanobiotix?

Arvinas (NASDAQ:ARVN) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Nanobiotix has lower revenue, but higher earnings than Arvinas.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$89.40M	5.80	-$80.80M	-$3.32	N/A
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A

Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, Arvinas and Arvinas both had 2 articles in the media. Nanobiotix's average media sentiment score of 0.67 beat Arvinas' score of 0.60 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arvinas presently has a consensus price target of $15.42, suggesting a potential upside of 91.99%. Nanobiotix has a consensus price target of $37.33, suggesting a potential downside of 2.73%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Nanobiotix's return on equity of 0.00% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Nanobiotix	N/A	N/A	N/A

Summary

Nanobiotix beats Arvinas on 7 of the 13 factors compared between the two stocks.

How does Arvinas compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Arvinas has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	16.97	-$153.49M	-$2.75	N/A
Arvinas	$89.40M	5.80	-$80.80M	-$3.32	N/A

In the previous week, Urogen Pharma had 7 more articles in the media than Arvinas. MarketBeat recorded 9 mentions for Urogen Pharma and 2 mentions for Arvinas. Urogen Pharma's average media sentiment score of 0.97 beat Arvinas' score of 0.60 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Urogen Pharma currently has a consensus price target of $41.63, suggesting a potential upside of 8.85%. Arvinas has a consensus price target of $15.42, suggesting a potential upside of 91.99%. Given Arvinas' higher probable upside, analysts plainly believe Arvinas is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Urogen Pharma has a net margin of -94.83% compared to Arvinas' net margin of -247.54%. Urogen Pharma's return on equity of 0.00% beat Arvinas' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Arvinas	-247.54%	-44.38%	-28.38%

Summary

Urogen Pharma beats Arvinas on 9 of the 17 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARVN vs. The Competition

Export

Metric	Arvinas	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$518.10M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.42	7.38	282.28	24.66
Price / Sales	5.80	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.19	16.96	10.96	6.07
Net Income	-$80.80M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-2.31%	-1.80%	-0.63%	-0.44%
1 Month Performance	-4.29%	-8.44%	-5.23%	-4.81%
1 Year Performance	8.22%	48.63%	62.07%	18.61%

Arvinas Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARVN Arvinas	2.8613 of 5 stars	$8.05 +0.2%	$15.42 +91.5%	+8.2%	$519.39M	$89.40M	N/A	420	Upcoming Earnings
SION Sionna Therapeutics	2.1718 of 5 stars	$45.38 -0.7%	$53.22 +17.3%	+178.5%	$2.06B	N/A	N/A	35	Positive News
AMLX Amylyx Pharmaceuticals	3.6725 of 5 stars	$19.49 +5.9%	$24.63 +26.3%	+163.1%	$2.05B	$87.37M	N/A	200	Positive News Upcoming Earnings
HRMY Harmony Biosciences	4.6579 of 5 stars	$36.01 +2.0%	$42.50 +18.0%	+2.4%	$2.04B	$868.45M	14.52	200	Upcoming Earnings Analyst Forecast
NBTX Nanobiotix	1.3159 of 5 stars	$40.18 +1.2%	$37.33 -7.1%	+469.9%	$2.01B	$36.87M	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARVN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arvinas (ARVN) Competitors

ARVN vs. SION, AMLX, HRMY, NBTX, and URGN

How does Arvinas compare to Sionna Therapeutics?

Summary

How does Arvinas compare to Amylyx Pharmaceuticals?

Summary

How does Arvinas compare to Harmony Biosciences?

Summary

How does Arvinas compare to Nanobiotix?

Summary

How does Arvinas compare to Urogen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arvinas (ARVN) Competitors

ARVN vs. SION, AMLX, HRMY, NBTX, and URGN

How does Arvinas compare to Sionna Therapeutics?

Do institutionals and insiders hold more shares of ARVN or SION?

Does the media favor ARVN or SION?

Do analysts rate ARVN or SION?

Which has higher earnings and valuation, ARVN or SION?

Is ARVN or SION more profitable?

Which has more volatility and risk, ARVN or SION?

Summary

How does Arvinas compare to Amylyx Pharmaceuticals?

Which has stronger earnings & valuation, ARVN or AMLX?

Which has more risk and volatility, ARVN or AMLX?

Do analysts rate ARVN or AMLX?

Is ARVN or AMLX more profitable?

Do insiders & institutionals believe in ARVN or AMLX?

Does the media favor ARVN or AMLX?

Summary

How does Arvinas compare to Harmony Biosciences?

Is HRMY or ARVN more profitable?

Does the media refer more to HRMY or ARVN?

Which has more volatility & risk, HRMY or ARVN?

Which has preferable valuation and earnings, HRMY or ARVN?

Do institutionals & insiders believe in HRMY or ARVN?

Do analysts rate HRMY or ARVN?

Summary

How does Arvinas compare to Nanobiotix?

Which has preferable earnings and valuation, ARVN or NBTX?

Which has more volatility and risk, ARVN or NBTX?

Does the media favor ARVN or NBTX?

Do insiders and institutionals have more ownership in ARVN or NBTX?

Do analysts recommend ARVN or NBTX?

Is ARVN or NBTX more profitable?

Summary

How does Arvinas compare to Urogen Pharma?

Which has stronger earnings & valuation, URGN or ARVN?

Does the media refer more to URGN or ARVN?

Which has more risk & volatility, URGN or ARVN?

Do analysts recommend URGN or ARVN?

Do insiders and institutionals believe in URGN or ARVN?

Is URGN or ARVN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN vs. The Competition

Arvinas Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools